A two-year single-site longitudinal assessment of brain and retinal atrophy in ocrelizumab-treated relapsing–remitting multiple sclerosis
Ocrelizumab is an effective treatment for relapsing–remitting multiple sclerosis (RRMS), but its impact on brain and retinal atrophy requires further investigation. To assess the effects of ocrelizumab on brain and retinal atrophy over two years and explore the relationship between imaging biomarkers, early inflammat...